Obesity is increasingly referred to as a chronic disease. This is also how it is defined in the recommendations of scientific ...

Nigeria has scored zero on obesity treatment and physical activity in a new global assessment of how countries are responding ...

As obesity medicine continues to evolve, integrating sleep health into obesity treatment plans is essential.Poor sleep ...

Three new studies reveal surprising insights on GLP-1 weight loss drugs, opioid treatment in pregnancy, and the real science ...

A Phase III trial of Rhythm Pharmaceuticals’ Imcivree (setmelanotide) failed to meet its primary endpoints in four rare, ...

Rhythm Pharmaceuticals said its Phase 3 trial for setmelanotide for patients with rare, genetically-driven obesities did not meet its primary endpoints.

California says it leads with science and compassion. By cutting treatment for chronic obesity, it is doing the opposite. If ...

Although the window for Rhythm Pharmaceuticals’ Imcivree to break out of the genetic obesity realm is quickly approaching with an upcoming FDA decision, a few other potential areas of expansio | The ...

Long-acting injectable CAB+RPV maintains high virologic suppression in patients with HIV and obesity, showing comparable real ...

The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing ...

AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs top healthcare stocks. On March 9, William Blair reiterated an Outperform ...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a clinical-stage biotechnology company developing a pipeline of ...